[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 412
Citations 0
Correction
June 06, 2012

Clarification of Conflict of Interest Disclosures in: Preventing Depression: A Global Priority

JAMA. 2012;307(21):2259. doi:10.1001/jama.2012.5453

Clarification of Conflict of Interest Disclosures: In a Viewpoint entitled, “Preventing Depression: A Global Priority,” published in the March 14, 2012, issue of JAMA (2012;307[10]:1033-1034), the conflict of interest disclosure for Dr Reynolds should have read as follows: “Dr Reynolds reported receiving pharmaceuticals for research studies from Bristol-Myers Squibb, Forest, Pfizer, and Lilly; receiving grants from the National Institute of Mental Health, National Institute on Aging, National Center on Minority Health and Health Disparities, National Heart, Lung, and Blood Institute, the Commonwealth of Pennsylvania, the John A Hartford Foundation, and the American Foundation for Suicide Prevention; and serving on the American Association for Geriatric Psychiatry editorial review board.” A letter regarding the correction appears in this issue. The article has been corrected online.

×